Eline Theunissen

Eline Theunissen is a psychopharmacology researcher whose work centres on controlled human studies of classical and novel psychedelics. Her publications and trial involvement span experimental, placebo‑controlled investigations in healthy volunteers (including low and microdoses of LSD), comparative acute‑effect studies (for example 2C‑B versus psilocybin), observational and laboratory studies of ayahuasca and creativity, and early phase clinical development of inhaled 5‑MeO‑DMT formulations for treatment‑resistant depression. She has contributed to methodological advances in human psychedelic research, including rigorous placebo‑controlled designs and citizen‑science approaches to microdosing, and routinely combines subjective, cognitive and psychophysiological outcome measures to characterise drug effects and safety profiles.

Theunissen's body of work situates mechanistic and phenomenological characterisation alongside clinical translation: from demonstrating dose‑dependent effects on pain perception and mood in controlled settings to participating in phase 1/2 safety and efficacy assessments of novel delivery systems (e.g. vaporised 5‑MeO‑DMT). Her publications reflect interdisciplinary collaboration across psychopharmacology, neuropsychology and clinical psychiatry, and have informed ongoing discussions about therapeutic potential, dosing paradigms (microdosing vs full doses) and responsible trial methodology in the contemporary renaissance of psychedelic research.